Immune Modulators for Treating COVID-19Research Question:
How do available treatments for COVID-19 compare?
Basic Study Information
Purpose:Location: University of Rochester Medical Center-Strong Memorial Hospital
ACTIV-1 IM is a master protocol designed to evaluate multiple investigational agents
treatment of moderately or severely ill patients infected with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). The research objectives are to evaluate each
respect to speed of recovery, mortality, illness severity, and hospital resource utilization.
Each agent will be evaluated as add-on therapy to the standard of care (SoC) in use
local clinics, including remdesivir (provided). The SoC may change during the course
study based on other research findings. Comparisons of the agents among themselves
is not a
The study population corresponds to moderately and severely ill patients infected
coronavirus disease 2019 (COVID-19) virus. Recruitment will target patients already
hospitalized for treatment of COVID-19 infection as well as patients being treated
COVID-19 infection in Emergency Departments while waiting to be admitted to the hospital.
Patients both in and out of the ICU are included in the study population.
Study Reference #: 20202874
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amanda Howell
Phone: (585) 273-1725
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search